Introduction {#s1}
============

Acute upper gastrointestinal bleeding (AUGIB) is a common medical emergency in the UK with an estimated incidence of 134 per 100 000 population,[@R1] roughly equating to one presentation every 6 min. Mortality following AUGIB over the last two decades has remained high at approximately 10%,[@R2] with several UK-wide audits revealing poor standards of care.[@R2] Multiple guidelines have been developed in an attempt to define quality standards in AUGIB and improve patient outcomes.[@R4] These unanimously acknowledge the importance of timely management within the first 24 hours as early resuscitation and endoscopy correlate with improved outcomes. Despite this, the 2015 UK National Confidential Enquiry into Patient Outcome and Death (NCEPOD) audit highlighted ongoing variations in practice and suboptimal care in patients with AUGIB.[@R7] As such, strategic initiatives remain necessary to address these long-standing deficiencies and drive sustained improvement.

The care bundle approach to medical care has become increasingly popular in recent years.[@R8] Care bundles comprise a pragmatic series of evidence-based interventions, which when performed together, lead to a better outcome than if performed individually.[@R8] Developed in 2004, the Sepsis Six bundle has achieved UK-wide implementation and has been shown to reduce mortality.[@R10] The 2014 British Society of Gastroenterology (BSG) and British Association for the Study of the Liver (BASL) care bundle for decompensated chronic liver disease was released in response to NCEPOD recommendations,[@R11] and has improved adherence to standards of care and reduced length of stay (LOS).[@R12] In endoscopy, implementation of the Quality Improvement in Colonoscopy bundle led to improvements in adenoma detection rates.[@R13] Thus, care bundles can facilitate the timely delivery of minimum standards of care, which can ultimately improve patient outcomes.[@R8] We propose that a consensus evidence-based care bundle specific for AUGIB and deliverable within the first 24 hours of presentation could improve the care and clinical outcomes of patients with AUGIB. We therefore aimed to produce an evidence and consensus-based care bundle for the first 24 hours from presentation in patients with suspected AUGIB. The bundle is intended to be used by all healthcare professionals involved in the initial management of patients with AUGIB. Detailed endoscopic management is beyond the scope of ward-based care and is therefore not included.

Methods {#s2}
=======

The UK AUGIB care bundle was developed as part of the BSG Endoscopy Quality Improvement Programme (EQIP).[@R15] The steering committee comprised a multidisciplinary group of experts from BSG, Association of Upper Gastrointestinal Surgeons, National Health Service (NHS) Blood and Transplant, Society for Acute Medicine, with trainee and patient representation. The consensus process involved a modified Delphi method. Members were assigned to working groups corresponding to different sections of the care bundle. Sequentially, these comprised: Recognition, Resuscitation, Risk Stratification, Rx (Treatment), Refer (referral for endoscopy) and Review (postendoscopic management). Each working group framed questions relevant to pre-endoscopic and postendoscopic interventions using the Patient, Intervention, Comparator, Outcome (PICO) method, and performed literature searches on PUBMED, EMBASE, and Cochrane Database of Systematic Reviews in June 2018. International AUGIB guidelines were also reviewed. For guidelines produced before 2013, searches were updated using original search strategies to identify more recent publications. Based on the PICO tables, statements relevant to early AUGIB management were formulated and the level of evidence for each statement appraised in accordance with Grading of Recommendations, Assessment, Development and Evaluations methodology.[@R16] Each statement was paired with a care bundle item. The process was peer-reviewed through multiple teleconferences. Once working groups had formulated initial evidence-based statements, a face-to-face meeting with anonymised electronic voting was arranged to evaluate consensus with statements and care bundle items. The level of agreement was measured on a five-point Likert Scale (A: strongly agree, B: agree, C: neither agree nor disagree, D: disagree, E: strongly disagree) following evidence appraisal for each statement. The number voting for each level was recorded and presented with each statement. A threshold of 80% agreement (rated A or B) was defined a priori to accept a statement; statement revisions were permitted if they did not meet this threshold. Each statement underwent up to three rounds of voting. Accepted statements were considered for incorporation into the final bundle after a separate voting process. A level of recommendation (weak/strong) was assigned to each statement. Although it is standard practice to align recommendations with the level of evidence, statements could receive discordant recommendations (eg, strong recommendation for low-quality evidence) if the perceived benefit in clinical practice outweighed the paucity of available evidence. The final version of the care bundle was reviewed and approved by stakeholder groups, including the BSG Clinical Services and Standards Committee, prior to submission for publication. Focused top-up searches were also performed in October 2019 to ensure that the evidence was updated prior to publication.

Consensus Statements {#s3}
====================

Following evidence review, the modified Delphi process reached consensus on 19 recommendations ([table 1](#T1){ref-type="table"}). These culminated into 14 corresponding care bundle items ([figure 1](#F1){ref-type="fig"}), enveloped within six management domains: Recognition, Resuscitation, Risk stratification, Rx (Treatment), Referral and Review (post-endoscopy care).

![Summary of the BSG-led acute upper gastrointestinal bleeding care bundle. NEWS, National Early Warning Score; PPI, proton pump inhibitor](flgastro-2019-101395f01){#F1}

###### 

Summary of recommendation statements

  Recommendation statement                                                                                                                                                                                                                     Level of evidence   Level of recommendation
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- -------------------------
  We recommend that patients with haematemesis, melaena, or coffee ground vomiting in the absence of an alternate diagnosis (eg, bowel obstruction) trigger the acute upper gastrointestinal bleeding (AUGIB) bundle.                          Low                 Strong
  We recommend that patients with suspected AUGIB should have urgent observations performed using a validated early warning score such as the National Early Warning Score (NEWS).                                                             Low                 Strong
  We recommend all patients with AUGIB be commenced on intravenous fluids. We recommend in haemodynamically unstable patients a crystalloid solution as a bolus of 500 mL in less than 15 min.                                                 Very low            Strong
  We recommend that red blood cell transfusion should follow a restrictive protocol (trigger: Hb \<70 g/L; target: 70--100 g/L). A higher trigger should be considered in patients with ischaemic heart disease or haemodynamic instability.   High                Strong
  We recommend that patients with AUGIB with ongoing haemodynamic instability are referred for critical care review.                                                                                                                           Very low            Strong
  We suggest that platelets should be given in active acute upper GI bleeding with a platelet count ≤50×10^9^/L, as per major haemorrhage protocols.                                                                                           Very low            Weak
  We recommend the Glasgow-Blatchford Score (GBS) is calculated at presentation with AUGIB.                                                                                                                                                    Moderate            Strong
  We recommend that patients with GBS ≤1 at presentation are considered for outpatient management.                                                                                                                                             Moderate            Strong
  We recommend intravenous terlipressin is given to all patients with suspected cirrhosis/variceal bleeding. However, caution should be exercised in patients with ischaemic heart disease or peripheral vascular disease.                     High                Strong
  We recommend giving intravenous antibiotics as per local protocol to patients with suspected cirrhosis/variceal bleeding.                                                                                                                    High                Strong
  We recommend continuing aspirin at presentation.                                                                                                                                                                                             Moderate            Strong
  We recommend interrupting P2Y12 inhibitors until haemostasis is achieved unless the patient has coronary artery stents, in which case, a decision should be undertaken after discussion with a cardiologist.                                 Moderate            Strong
  We recommend interrupting warfarin therapy at presentation.                                                                                                                                                                                  Low                 Strong
  We recommend interrupting direct oral anticoagulant therapy at presentation.                                                                                                                                                                 Low                 Strong
  We recommend endoscopy is offered to patients admitted with suspected AUGIB within 24 hours of presentation. Patients with ongoing haemodynamic instability will require more urgent endoscopy after resuscitation.                          Low                 Strong
  We suggest that the endoscopy report should be reviewed by the ward team.                                                                                                                                                                    Very low            Strong
  We suggest that all patients with varices or those requiring endoscopic therapy are referred to a specialist gastroenterology service.                                                                                                       Low                 Strong
  We recommend patients with bleeding from ulcers with high-risk stigmata at endoscopy receive high-dose intravenous proton pump inhibitor (PPI) therapy; high-dose oral PPIs may be considered as an alternative.                             High                Strong
  We recommend patients with AUGIB in whom antithrombotic therapy is interrupted have a clear plan for resumption.                                                                                                                             Low                 Strong

Recognition {#s4}
===========

We recommend that patients with haematemesis, melaena or coffee ground vomiting (CGV) in the absence of an alternate diagnosis (eg, bowel obstruction) trigger the AUGIB bundle {#s4-1}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Level of evidence: Low

Level of recommendation: Strong

Agreement: 100%

Bundle recommendation: Trigger bundle if haematemesis, melaena or CGV (100% agreement)

Haematemesis and melaena are recognised symptoms of AUGIB. CGV refers to emesis that contains dark altered blood not due to any other cause such as bowel obstruction or sepsis. The appropriateness of including CGV as a trigger for the AUGIB bundle was evaluated. A recent study (n=3012) prospectively compared outcomes following presentation with CGV compared with overt haematemesis and/or melaena.[@R17] Clinical severity measured using risk stratification tools were all significantly lower in the isolated haematemesis group than in the CGV group, as CGV was associated with older patients with comorbidity. Although haematemesis was independently associated with higher rates of haemostatic intervention and rebleeding than CGV, there were no significant differences in the composite outcome of transfusion requirement, endoscopic intervention or death between presenting symptoms. Hence CGV should be considered a presenting feature of AUGIB.

Resuscitation {#s5}
=============

We recommend that, on admission or presentation with suspected AUGIB, urgent observations be performed using a validated early warning score such as the National Early Warning Score (NEWS) {#s5-1}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Level of evidence: Low

Level of recommendation: Strong

Agreement: 80%

Bundle recommendation: Perform NEWS (100% agreement)

All patients with AUGIB require urgent assessment of their haemodynamic status followed by reassessment at regular intervals. Early warning scores serve as a composite indicator of a patient's physiological status and are used to identify deteriorating patients and trigger medical interventions. These can be used to determine bleeding severity, screen for rebleeding in stable patients, guide fluid resuscitation and determine intervention, for example, frequency of observations, escalation of care, and so on. The role of early warning scores in AUGIB has been presented in a single-centre study (n=202) which compared a Modified Early Warning Score (MEWS) based on five admission parameters (systolic blood pressure, heart rate, respiratory rate, temperature and consciousness level) with the Glasgow-Blatchford Score (GBS) and the Pre-endoscopic Rockall (PER) Score in predicting outcomes.[@R18] There was significant correlation between the admission MEWS and the outcomes of hospital admission and death (p\<0.001). MEWS \>2 was superior for predicting mortality (area under the receiver operating characteristics curve (AUROC) 0.772, p\<0.001) compared with GBS \>13 (AUROC 0.679, p=0.022) and PER Score (AUROC 0.767, p\<0.001). MEWS \>1 was also predictive of transfusion requirements (AUROC 0.584, p=0.047), but not rebleeding (AUROC 0.617, p=0.064) or endoscopic therapy (AUROC 0.508, p=0.862).[@R18]

NEWS has received endorsement by the Royal College of Physicians and NHS England for use in all acutely ill patients.[@R19] To align with these recommendations, we recommend the use of NEWS, or a similarly validated early warning score, at presentation with suspected AUGIB.

We recommend all patients with AUGIB be commenced on intravenous fluids. We recommend a crystalloid solution with a bolus of 500 mL over less than 15 min, in haemodynamically unstable patients {#s5-2}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Level of evidence: Very low

Level of recommendation: Strong

Agreement: 100%

Bundle recommendation: Commence intravenous crystalloid (80% agreement)

Haemodynamic instability is defined by the National Institute for Health and Care Excellence (NICE) as active bleeding where blood pressure or pulse cannot be normalised or where rapid intravenous fluids are required to maintain haemodynamic stability.[@R5] There are no randomised controlled trials (RCTs) comparing different fluid regimens in AUGIB.

Two small non-randomised studies assessed the volume of fluid administration in AUGIB. The first (n=51) included patients with variceal bleeding and haemorrhagic shock and compared dopamine with restricted fluid versus liberal fluids only.[@R20] There were no significant differences in mortality or LOS, but evidence of reductions in acute respiratory distress syndrome, multiorgan failure and sepsis in favour of the dopamine group. The second associated early intensive resuscitation in AUGIB with reduced rates of mortality and myocardial infarction.[@R21] However, the intervention involved a physician providing dedicated one-to-one input (no other clinical duties other than caring for the patient with AUGIB) and therefore cannot be proposed as standard care in routine clinical practice.

The NICE guideline on intravenous fluids recommends fluid resuscitation with 500 mL crystalloid over less than 15 min.[@R22] This is based on a Cochrane review comparing crystalloids with colloids in critically ill patients.[@R23] The European Society of Gastrointestinal Endoscopy (ESGE) AUGIB guidelines[@R6] contain a recommendation on prescribing intravenous fluids based on this Cochrane review[@R23] and a high-quality single-centre RCT.[@R24] ESGE guidelines recommend prompt intravascular volume replacement using crystalloid fluids if haemodynamic instability exists.[@R6] Fluid administration has not featured in other AUGIB guidelines.

Regardless of haemodynamic status at presentation, we recommend that all patients with AUGIB should be commenced on intravenous fluid replacement and that monitoring of NEWS and clinical review are required to determine the infusion rate.

We recommend that red blood cell (RBC) transfusion should follow a restrictive protocol (trigger: Hb \<70 g/L; target: 70--100 g/L). A higher trigger should be considered in patients with ischaemic heart disease or haemodynamic instability {#s5-3}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Level of evidence: High

Level of recommendation: Strong

Agreement: 100%

Bundle recommendation: Transfuse if Hb \<70 g/L with a target of 70--100 g/L (100% agreement)

Five RCTs have assessed the use of different transfusion thresholds;[@R25] these were summarised in a systematic review (n=1965).[@R30] Ninety-three per cent of patients were derived from two RCTs which included both variceal and non-variceal AUGIB.[@R26] Only one RCT included participants regardless of age, comorbidity or history of ischaemic heart disease.[@R26] The study by Villanueva et al (n=889) was a single-centre Spanish RCT that compared a threshold of 70 g/L with 90 g/L.[@R27] All participants received endoscopy within 6 hours. The study by Jairath *et al* was a multicentre UK cluster randomised RCT that compared a threshold of 80 g/L with 100 g/L.[@R26] In the meta-analysis, a restrictive transfusion strategy was associated with a reduction in all-cause mortality at 30 days (26 fewer deaths per 1000; 95% CI 2 to 42); rebleeding (57 fewer rebleeding episodes per 1000; 95% CI 21 to 81), transfusion requirement (mean difference −1.73 RBC units; 95% CI −2.36 to −1.11); number of people who required a transfusion (276 fewer per 1000; 95% CI 164 to 361) and LOS (mean difference −1.9 days; 95% CI 3.34 to 0.46).[@R30] No difference was found between the variceal and non-variceal subgroups. No RCTs included participants with exsanguinating haemorrhage, where haemoglobin may not be an accurate measure of blood loss.[@R31] In such cases, patients should be managed in line with major haemorrhage guidelines.[@R32] Rates of RBC transfusion should be guided by the speed of blood loss and the level of haemodynamic compromise.[@R32]

We recommend that patients with AUGIB with ongoing haemodynamic instability are referred for critical care review {#s5-4}
-----------------------------------------------------------------------------------------------------------------

Level of evidence: Very low

Level of recommendation: Strong

Agreement: 100%

Bundle recommendation: *If haemodynamically unstable, consider activating major haemorrhage protocol and arranging critical care review (added as standalone statement in bundle)*

The study by Baradarian *et al* associated intensive monitoring and management of haemodynamic instability with improved outcomes.[@R21] Patients with AUGIB may also suffer complications caused by non-hypovolaemic causes of shock, for example, sepsis in patients with cirrhosis. Haemodynamic instability per se should not be the sole determinant for critical care admission.[@R33] In cases of ongoing haemodynamic instability despite adequate resuscitative efforts, activation of the major haemorrhage protocol should be considered in addition to early referral to a critical care specialist in order to optimise circulatory management.[@R32]

We suggest that platelets should be given in active AUGIB with a platelet count ≤50 × 10^9^/L, as per major haemorrhage protocols {#s5-5}
---------------------------------------------------------------------------------------------------------------------------------

Level of evidence: Very low

Level of recommendation: Weak

Agreement: 90%

Bundle recommendation: *Keep platelet count \>50 (included as part of major haemorrhage protocol, therefore no separate statement required*)

No RCTs have assessed the role of platelet transfusions or platelet transfusion thresholds.[@R35] There is little evidence for the effectiveness of platelet transfusions or the optimal dose when a patient with a thrombocytopenia is actively bleeding.[@R36] In patients without pre-existing thrombocytopenia, acquired thrombocytopenia may be a late event in major haemorrhage, occurring after blood loss of at least 1.5 total blood volumes.[@R32] Guidance for a platelet transfusion threshold in major bleeding is based on expert opinion only, and is consistently recommended by NICE[@R5] and the British Society for Haematology.[@R32] Due to the limited evidence and its coverage within the major haemorrhage protocol, a separate bundle statement for thrombocytopaenia correction was not included.

Risk stratification {#s6}
===================

We recommend GBS is calculated at presentation with AUGIB {#s6-1}
---------------------------------------------------------

Level of evidence: Moderate

Level of recommendation: Strong

Agreement: 100%

Bundle recommendation: Calculate GBS (100% agreement)

We recommend that patients with GBS ≤1 at presentation are considered for outpatient management {#s6-2}
-----------------------------------------------------------------------------------------------

Level of evidence: Moderate

Level of recommendation: Strong

Agreement: 100% Agreement

Bundle recommendation: Consider discharge if GBS 0 or 1 (100% agreement)

Several comparative studies have assessed pre-endoscopy and postendoscopy risk scores in AUGIB.[@R38] These studies confirm GBS is the best at predicting the clinically important composite end point of need for hospital-based intervention (transfusion, endoscopic therapy, interventional radiology, surgery) or death, with high sensitivity at 98.6%.[@R39] The clinical utility of existing risk scores to identify patients at high risk of poor outcomes appear limited. The AIMS65 and PER Scores appear best at predicting death after AUGIB,[@R41] and use of the full Rockall Score following endoscopy has previously been recommended to predict mortality.[@R5] However the AUROC figures for mortality using these scores are relatively low.[@R39] The accuracy of risk scores to identify need for endoscopic therapy or rebleeding is also relatively low.[@R38]

A systematic review of pre-endoscopy risk scores found that GBS was the optimal pre-endoscopy risk score with GBS of zero demonstrating high sensitivity but low specificity for predicting adverse outcomes.[@R40] Although GBS of zero has historically been used to identify very low-risk patients suitable for outpatient management,[@R5] recent large multicentre studies have suggested this threshold could be increased to GBS ≤1.[@R38] This GBS threshold strategy has been recommended by recent international AUGIB guidelines.[@R4] The recently described pre-endoscopic CANUKA Score shows promise in identifying low-risk patients presenting with UGIB, however only 7% patients were encompassed by its low-risk threshold, compared with 24% using the GBS ≤1 threshold.[@R58] Further data on this score are awaited.

RX (Treatment) {#s7}
==============

We recommend intravenous terlipressin is given to all patients with suspected cirrhosis/variceal bleeding. However, caution should be exercised in patients with ischaemic heart disease or peripheral vascular disease {#s7-1}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Level of evidence: High

Level of recommendation: Strong

Agreement: 100%

Bundle recommendation: Intravenous terlipressin 2 mg four times a day in case of suspected variceal bleeding (80% agreement)

Variceal bleeding should be suspected in patients presenting with AUGIB who have known cirrhosis or have clinical parameters that would suggest cirrhosis. The UK variceal bleed guidelines recommend administering terlipressin or somatostatin as soon as variceal bleeding is suspected,[@R59] for up to 5 days or until attainment of haemostasis, with octreotide as an alternative. The efficacy of intravenous terlipressin in variceal bleeding has been presented in a Cochrane meta-analysis of 22 RCTs (n=1609).[@R60] Seven studies (n=443) compared terlipressin to placebo, of which five were considered to be high quality. This showed a significant reduction in all-cause mortality compared with placebo (34% relative risk reduction), improved haemostasis and reduced transfusion requirement. Similar results were found in an updated meta-analysis in 2012.[@R61] A more recent multicentre RCT (n=780) reported non-inferiority of terlipressin compared with octreotide and somatostatin, with no difference in outcomes of haemorrhage control, rebleeding and mortality.[@R62] The BSG/BASL cirrhosis bundle suggests caution in patients with known ischaemic heart disease or peripheral vascular disease and mandatory ECG assessment in patients aged over 65 years.[@R11]

We recommend giving intravenous antibiotics to all patients with suspected cirrhosis/variceal bleeding {#s7-2}
------------------------------------------------------------------------------------------------------

Level of evidence: High

Strength of recommendation: Strong

Agreement: 100%

Bundle recommendation: Intravenous antibiotics if suspected cirrhosis/variceal bleeding (100% agreement)

Bacterial infections are common in patients with cirrhosis and AUGIB and are associated with rebleeding and mortality.[@R63] A Cochrane meta-analysis of 12 RCTs (n=1241) concluded that antibiotic prophylaxis in this context was superior to placebo in reducing mortality, bacterial infections, rebleeding and LOS.[@R64] The benefit of antibiotic prophylaxis has also been observed following endoscopic haemostasis for peptic ulcer bleeding.[@R65] There is evidence to support the use of intravenous prophylactic antibiotics over oral agents. Fernandez *et al* [@R67] randomised patients (n=111) with AUGIB and cirrhosis to either oral norfloxacin (400 mg twice daily) or intravenous ceftriaxone (1 g/day) for 7 days, and assessed outcomes within 10 days. Patients assigned to intravenous ceftriaxone had lower rates of proven infections, bacteraemia and spontaneous bacterial peritonitis. In accordance with the BSG/BASL cirrhosis bundle, patients with cirrhosis and AUGIB should be empirically managed as variceal bleeding and commenced on antibiotic prophylaxis according to local antimicrobial policy.

### We recommend continuing aspirin at presentation {#s7-2-1}

Level of evidence: Moderate

Level of recommendation: Strong

Agreement: 90%

Bundle recommendation: Continue aspirin (80% agreement)

### We recommend interrupting P2Y12 inhibitors until haemostasis is achieved unless the patient has coronary artery stents, in which case, a decision should be undertaken after discussion with a cardiologist {#s7-2-2}

Level of evidence: Moderate

Level of recommendation: Strong

Agreement (Round 3): 80%

Bundle recommendation: Unless the patient has major AUGIB, continue P2Y12 inhibitor in patients with coronary artery stents until discussion with cardiology (60% agreement---rejected)

### We recommend interrupting warfarin therapy at presentation {#s7-2-3}

Level of evidence: Low

Level of recommendation: Strong

Agreement: 80%

Bundle recommendation: Suspend warfarin (100% agreement)

### We recommend interrupting direct oral anticoagulant (DOAC) therapy at presentation {#s7-2-4}

Level of evidence: Low

Level of recommendation: Strong

Agreement: 90%

Bundle recommendation: Suspend DOAC (100% agreement)

Antithrombotic therapy {#s8}
======================

Antithrombotic therapy confers a balance of beneficial antithrombotic effects versus risk of AUGIB. In AUGIB, emergency endoscopy can provide effective haemostasis, and antithrombotic therapy may be temporarily interrupted depending on the indication.[@R68]

Aspirin {#s9}
=======

In patients on low-dose aspirin for secondary prevention, aspirin discontinuation is associated with a threefold increased risk of cardiovascular or cerebrovascular events, the majority of which occurred within 7--10 days.[@R69] An RCT comparing continuation of low-dose (80 mg) aspirin therapy or discontinuation (placebo) following endoscopic haemostasis for peptic ulcer bleeding found increased incidence of recurrent bleeding in the continuation group (10.3% vs 5%) but lower all-cause mortality (1.3% vs 12.9%).[@R71] All patients received intravenous proton pump inhibitor (PPI) therapy. It should be noted that aspirin was discontinued for 8 weeks in the placebo group.

P2Y12 receptor antagonists {#s9-1}
--------------------------

P2Y12 receptor antagonists, for example, clopidogrel, prasugrel and ticagrelor, are commonly co-prescribed with aspirin as DAPT. DAPT is generally recommended for 12 months after deployment of drug-eluting coronary artery stents or 1 month for bare metal stents. There is a high risk of stent thrombosis, with up to a 40% risk of acute myocardial infarction or death if DAPT therapy is discontinued within this period.[@R72] Ideally, DAPT for coronary stents should be continued due to the consequences of stent thrombosis, and it is important to liaise with a cardiologist in the emergency setting. In the event of severe haemorrhage, it may be necessary to temporarily discontinue the P2Y12 inhibitor, but aspirin should be continued,[@R73] with the aim to restart the P2Y12 inhibitor within 5 days .[@R74] This recommendation is consistent with international guidelines,[@R68] but due to the lack of AUGIB-specific studies and the complexity of the statement, the steering group did not recommend this statement as a stand-alone item in the care bundle.

Warfarin {#s10}
========

Indications for warfarin can be characterised into low risk or high risk for thrombosis.[@R68] Warfarin can be interrupted on presentation with AUGIB, but a plan for resumption should be made. Specific advice on the management of patients in whom reversal of anticoagulation is indicated are outside the scope of this bundle but are available in published guidelines.[@R68]

Direct oral anticoagulants {#s11}
==========================

Dabigatran is a thrombin inhibitor, whereas rivaroxaban, apixaban and edoxaban are factor Xa inhibitors. Unlike warfarin, DOACs have relatively short half-lives, which may be prolonged in renal failure. For minor AUGIB, it is usually sufficient to withhold DOAC therapy and allow the effect to dissipate; severe AUGIB is challenging and advice should be sought from a haematologist. In the case of life-threatening haemorrhage, idarucizumab has been developed as an antidote for dabigatran,[@R76] and andexanet for the antifactor Xa inhibitors.[@R77]

Refer {#s12}
=====

We recommend endoscopy is offered to patients admitted with suspected AUGIB within 24 hours of presentation. Patients with ongoing haemodynamic instability will require more urgent endoscopy after resuscitation {#s12-1}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Level of evidence: Weak

Level of recommendation: Strong

Agreement: 90%

Bundle recommendation: Referral to ensure that endoscopy is performed within 24 hours of presentation (100% agreement)

Endoscopy is the primary diagnostic and therapeutic modality in AUGIB. Time to endoscopy, that is, time from admission/inpatient presentation to endoscopy, is a recognised quality metric in AUGIB.

Two systematic reviews which studied the effect of early endoscopy (≤24 hours) found no benefit on mortality and the need for surgery but identified a reduction in LOS.[@R78] Several studies assessed the effect of endoscopy timing on clinical outcome in non-variceal AUGIB, although these differed in study design. One US study identified delayed endoscopy (\>24 hours after admission) as an independent predictor of mortality in both variceal bleeding and non-variceal AUGIB.[@R80] The role of very early endoscopy (\<12 hours) in patients with NVUGIB remains controversial.[@R81] Endoscopy within 12 hours (vs 12--24 hours) has been associated with lower transfusion requirements.[@R81] One retrospective analysis assessed timing of endoscopy in low-risk (GBS ≤12) versus high-risk (GBS ≥12) patients.[@R82] The timing of endoscopy did not impact on inpatient mortality in low-risk patients, but was significant in the high-risk group, where a threshold of 13 hours was optimal for predicting survival.[@R82] No differences were reported for transfusion requirements, rebleeding or need for surgery, which suggests that mortality in these patients may be unrelated to AUGIB.[@R82] An RCT from Hong Kong compared \<6 hours vs \<24 hours endoscopy in high-risk patients (GBS ≥12),[@R83] with preliminary results reporting no difference in major outcomes.

In contrast, a retrospective study (n=81) found no differences in clinical outcomes (mortality, rebleeding or surgery or LOS) between patients receiving endoscopy within 3 hours vs 48 hours. There was however a higher need for endoscopic therapy in the early endoscopy group (p=0.002).[@R84]

Several studies have associated very early endoscopy (\<12 hours) with adverse outcomes. A retrospective study (n=361) reported that patients undergoing endoscopy within 12 hours for AUGIB had a fivefold increased risk of incurring the composite outcome of rebleeding, surgical or radiological intervention or need for repeat endoscopic intervention.[@R85] Other confounders may exist, but one possible explanation could be inadequate resuscitation, as patients who underwent early endoscopy had significantly lower blood pressure and higher heart rate. A nationwide cohort study of patients with peptic ulcer bleeding from Denmark (n=12 601) associated endoscopy undertaken too early, or too late, with higher mortality, particularly in patients with higher levels of comorbidity or haemodynamic instability.[@R86] The authors suggested that a period of 6--12 hours prior to endoscopy may allow time for resuscitation and medical optimisation.

Most guidelines recommend endoscopy for all patients within 24 hours, and for patients with haemodynamic instability to undergo more urgent endoscopy.[@R5] ESGE guidelines also recommend very early endoscopy in those with contraindications to the interruption of anticoagulation, although data were limited.[@R6] For suspected acute variceal bleeding, the European and American guidelines suggest endoscopy with 12 hours.[@R88] However, the 2015 UK variceal bleeding guidance proposes endoscopy within 24 hours for all, except for unstable patients who should have endoscopy immediately after resuscitation,[@R59] as changing the timing of endoscopy to within 12 hours has not been shown to be associated with a survival benefit.[@R90]

Based on the available evidence and international guidelines, we recommend that all patients with AUGIB undergo endoscopy within 24 hours of admission, with earlier endoscopy for those with ongoing haemodynamic instability. The endoscopy referral or request should be made in a timely manner in order to achieve this outcome.[@R91]

Review {#s13}
======

We suggest that the endoscopy report should be reviewed by the ward team {#s13-1}
------------------------------------------------------------------------

Level of evidence: Very low

Level of recommendation: Strong

Agreement: 90%

Bundle recommendation: Review endoscopy report (100% agreement)

The endoscopy report provides an overview of each procedure. For AUGIB, this should include endoscopic findings and haemorrhagic stigmata, therapies administered, certainty of haemostasis, complications, further management and rebleeding plan.[@R7] One Canadian prospective study studied the impact of a checklist on the endoscopy report in patients with non-variceal AUGIB,[@R93] which included instructions on diet, drugs and discharge. Checklist compliance led to reductions in LOS. Although the impact of a rebleeding plan has not been specifically studied, this featured in the NCEPOD recommendations as a pragmatic and clinically relevant standard of care.[@R7] On their return to the ward following endoscopy, the patient and endoscopy report should be reviewed by the receiving ward team and management recommendations instigated.

We suggest that all patients with varices or those requiring endoscopic therapy are referred to a gastroenterology service {#s13-2}
--------------------------------------------------------------------------------------------------------------------------

Level of evidence: Low

Level of recommendation: Strong

Agreement: 90%

Bundle recommendation: Refer to GI specialist if requiring therapeutic endoscopy (100% agreement)

Several studies have assessed the role of specialist care for AUGIB under gastroenterology teams. A single-centre prospective UK study by Sanders *et al* assessed the outcomes of 900 consecutive patients with AUGIB admitted to a dedicated GI bleeding unit.[@R94] All patients received protocolised care by dedicated gastroenterologists and nurses, and had access to 24 hours endoscopy and interventional radiology. Compared with data from the 1995 UK audit of AUGIB, mortality adjusted by PER and post-endoscopy Rockall Scores were significantly lower in the specialist unit. This study echoed the findings of a previous retrospective UK-based study without propensity matching.[@R95] A retrospective Italian multicentre analysis (n=13 427) reported that specialist gastroenterology care was associated with reduced 30-day mortality (OR 0.55, 95% CI 0.37 to 0.82), which remained significant after propensity adjustment and in patients receiving endoscopy.[@R96]

Based on the study by Sanders *et al*, the Scottish Intercollegiate Guidelines Network recommended that patients with AUGIB should be admitted, assessed and managed in a dedicated gastrointestinal bleeding unit.[@R87] We recommend that patients with endoscopically confirmed AUGIB, particularly those requiring therapeutic haemostasis, should be referred to a specialist service for ongoing input. Patients with evidence of varices are at risk of decompensation from underlying cirrhosis, and should also be referred for specialist care and follow-up.

We recommend patients with bleeding from ulcers with high-risk stigmata at endoscopy receive high dose intravenous proton pump inhibitor (PPI) therapy; high-dose oral PPIs may be considered as an alternative {#s13-3}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Level of evidence: *High*

Level of recommendation: Strong

Agreement: 90%

Bundle recommendation: PPI if high risk ulcer post-endoscopy (100% agreement)

The role of PPI infusion in patients with high-risk, non-variceal AUGIB is supported by meta-analysis data.[@R97] The NICE guidelines recommend offering PPI to patients with non-variceal AUGIB with endoscopic stigmata of recent haemorrhage,[@R5] whereas ESGE recommends intravenous PPI for patients requiring endoscopic haemostasis or ulcers with adherent clot.[@R6] Although PPI infusion (80 mg bolus followed by 8 mg/hour for 72 hours) was recommended, intermittent intravenous PPI and oral high-dose PPI could be considered as alternatives.[@R4]

A meta-analysis of 13 RCTs comparing various regimens of intermittent intravenous PPI with PPI infusion following endotherapy for high-risk bleeding peptic ulcers reported non-inferiority with intermittent PPI therapy for the outcomes of rebleeding, mortality, urgent interventions, LOS or transfusion requirements.[@R99] The authors concluded that intermittent bolus regimens could be used as an alternative to infusion therapy.

RCT and meta-analysis data have failed to demonstrate superiority of PPI therapy based on dosage or route of PPI administration as an adjunct to endoscopic therapy for peptic ulcer disease.[@R100] The Asia-Pacific guidelines suggest that, as an adjunct to endoscopic treatment, high-dose oral PPI can be used to prevent rebleeding.[@R4]

We recommend patients with AUGIB in whom antithrombotic therapy is interrupted have a clear plan for resumption {#s13-4}
---------------------------------------------------------------------------------------------------------------

Level of evidence: *Low*

Level of recommendation: Strong

Agreement: 100%

Bundle recommendation: *Posthaemostasis antithrombotic plan (100% agreement*)

Antithrombotic therapy is often stopped following AUGIB and a clear plan for resumption not made on discharge. Antithrombotic resumption is associated with improved survival and reduced incidence of thrombotic complications.[@R103] Thus, all patients in whom antithrombotic therapy has been interrupted should have a clear plan for resumption.

Detailed discussion on the timing of antithrombotic resumption is beyond the scope of this bundle but is available from international guidelines.[@R4] Inclusion of a statement on resumption of antithrombotics was unanimously supported by the working group.

Discussion {#s14}
==========

Despite the availability of multiple high-quality international guidelines, recent evidence confirms persisting poor performance in managing patients with AUGIB.[@R7] The BSG EQIP has identified a clinical need to improve the quality of endoscopy and service provision in AUGIB. Previous interventions in the UK, for example in colonoscopy training and certification, provided by the Joint Advisory Group on Gastrointestinal Endoscopy, have been shown to significantly improve performance and outcomes in clinical practice.[@R104] In addition, other care bundles such as the BSG/BASL cirrhosis bundle have led to improvements in patient-centred outcomes.[@R12]

Many of the areas for possible improvement in AUGIB management are in the pre-endoscopy and post-endoscopy care of patients either admitted with AUGIB to hospital or who develop bleeding while hospitalised with another condition. We have therefore convened a multidisciplinary, multisociety development group to construct a care bundle targeted at non-specialist staff in emergency departments, acute medical or surgical wards aiming to improve management in the first 24 hours of care.

In developing this bundle, we have focused on six domains with 14 bundle items. The care bundle comprises a series of evidence-based measures which are associated with improved outcomes compared with if they were not performed. In addition, preliminary evidence has reported improved outcomes when using the bundle.[@R105] The brevity and choice of items make this a simple and quick tool to enhance utilisation in busy clinical practice. We believe that, if implemented, the AUGIB bundle could ensure standardised, evidence-based care of the highest quality in hospitals in the UK and in other international healthcare environments.
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